Faculty Disclosures

Article Outline

 

The authors who contributed to this publication have disclosed the following industry relationships:

Elizabeth A. Bower, MD, MPH, has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.

Mitchell S. V. Elkind, MD, MS, FAAN, has received compensation during the past 3 years from Boehringer Ingelheim Pharmaceuticals, Inc, for consulting and as a member of its Speakers' Bureau. Boehringer Ingelheim Pharmaceuticals, Inc, has provided compensation for the writing of Dr Elkind's article included in this supplement. He also serves on the adjudication committee for a stroke prevention trial (PRoFESS) for Boehringer Ingelheim Pharmaceuticals, Inc, but does not receive personal compensation for this. He received research support from BMS–Sanofi Pharmaceutical Partnership for an ancillary study to a clinical trial. The study is the Levels of Inflammatory Markers in Treatment of Stroke (LIMITS) study, which is an observational study within the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. SPS3 is a National Institute of Neurological Disorders and Stroke–funded trial of secondary stroke prevention. In addition, he received compensation over the past 3 years as a member of the BMS-Sanofi Speakers' Bureau. In addition, he has received compensation over the past 3 years from GlaxoSmithKline for consulting on a clinical trial in the prevention of prostate cancer. He has received compensation in the past 3 years from Daiichi Sankyo for consulting on interpretation of their clinical trial results for prasugrel, an antiplatelet drug, as those results relate to stroke. He also expects to receive compensation from Pfizer, Inc, for consulting. And has received compensation over the past 3 years from Jarvik Heart for serving as a member of a clinical events adjudication committee for one of its clinical trials. And, lastly, has received compensation in research support over the past 3 years from diaDexus, Inc, and over the past year as a member of its Speakers' Bureau.

Donald E. Girard, MD, has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.

Dara Jamieson, MD, has served in the past year as a speaker for Merck & Co., and Boehringer Ingelheim Pharmaceuticals, Inc., receiving honoraria from each company. During the past year, she also served as a consultant for Merck & C0., Boehringer Ingelheim Pharmaceuticals, Inc., and Bayer.

Helmi L. Lutsep, MD, has been on the international advisory board for Boehringer Ingelheim Pharmaceuticals, Inc. and on its Speakers' Bureau. Thus far, Dr Lutsep has received no money for the advisory board position, itself—only compensation for speaking during each of the years serving in this capacity.